8-K: Humana Q3 2025: Adjusted EPS Affirmed, MA Outlook Improves

Humana reported Q3 2025 Adjusted EPS of $3.24, affirmed its full-year 2025 Adjusted EPS guidance of approximately $17.00, and improved its individual Medicare Advantage membership decline outlook.

Summary

• Reported Third Quarter 2025 GAAP earnings per share (EPS) of $1.62 and Adjusted EPS of $3.24.
• Year-to-date (YTD) GAAP EPS was $16.43 and Adjusted EPS was $21.10.
• The Insurance segment benefit ratio for Q3 2025 was 91.1 percent, aligning with the company's expectation of 'just above 91 percent'.
• Full Year 2025 GAAP EPS guidance was updated to 'approximately $12.26' from the previous estimate of 'approximately $13.77'.
• Full Year 2025 Adjusted EPS guidance was affirmed at 'approximately $17.00'.
• Full Year 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent was affirmed.
• Individual Medicare Advantage membership guidance for FY 2025 was updated to anticipate a decline of 'approximately 425,000 members', an improvement from the previous guidance of 'up to 500,000 members', driven by stronger retention and better-than-expected sales.
• The company is actively preparing for the January 1, 2026 launch of new Michigan and Illinois integrated dual eligible programs, and the carve-in of dual eligibles into the South Carolina Medicaid program.
• CenterWell Primary Care experienced growth of 56,600 patients, or nearly 15 percent, compared to December 31, 2024.
• CenterWell Pharmacy showed strong growth in Specialty volumes and Direct to Consumer offerings, exceeding previous expectations in Q3 2025.
• Consolidated operating cash flows for YTD 2025 decreased to $2,573 million from $3,494 million in YTD 2024.
• Debt-to-total capitalization decreased to 40.3 percent at September 30, 2025, from 42.3 percent at September 30, 2024.
• Days in claims payable (DCP) decreased to 33.2 days at September 30, 2025, from 40.7 days at September 30, 2024.

Sentiment

Score: 7

Explanation: The company affirmed its key Adjusted EPS guidance for the full year and improved its outlook for individual Medicare Advantage membership decline, indicating better-than-expected retention and sales. Strategic growth in CenterWell and Medicaid, along with preparations for significant program launches in 2026, show positive momentum. However, GAAP EPS guidance was lowered, and operating cash flows decreased year-over-year, reflecting some underlying challenges and non-recurring charges.

Positives

• Affirmed Full Year 2025 Adjusted EPS guidance of approximately $17.00, indicating core operational performance is on track.
• Improved Full Year 2025 individual Medicare Advantage membership guidance to a decline of approximately 425,000 members, better than the previous expectation of up to 500,000, driven by stronger retention and better-than-expected sales.
• Demonstrated growth in CenterWell Primary Care with 56,600 new patients, a nearly 15% increase compared to December 31, 2024.
• CenterWell Pharmacy achieved strong growth in Specialty volumes and Direct to Consumer offerings, surpassing previous expectations in Q3 2025.
• Actively preparing for significant Medicaid program launches and expansions in Michigan, Illinois, and South Carolina effective January 1, 2026, furthering long-term strategic advancement.
• Reported higher favorable prior period medical claims reserve development in Q3 2025 and YTD 2025, the majority of which was anticipated.
• Achieved administrative cost efficiencies through value creation initiatives and operating leverage from increased revenues due to the Inflation Reduction Act (IRA).
• Debt-to-total capitalization improved to 40.3% at September 30, 2025, from 42.3% year-over-year, reflecting balance sheet efficiency.
• Days in claims payable (DCP) decreased to 33.2 days from 40.7 days year-over-year, indicating faster claims processing.
• CenterWell's Net Promoter Score increased by 250 basis points year over year, reflecting sustained improvements in patient experience.
• OneHome expanded the percentage of members in value-based home health models by nearly 17% YTD, exceeding the previously stated expectation of 15% for FY 2025.
• Committed to achieving individual Medicare Advantage pretax margin of at least 3% over time and anticipates doubling individual MA pretax margin in 2026 (normalizing for Stars).
• Expects improved retention to be an important driver of net membership growth in 2026, with most new sales anticipated on contracts with 4+ Stars.
• Efforts to strengthen the Stars program are progressing, with initiatives aimed at achieving Top Quartile Stars results in Bonus Year 2028.
• Group Medicare Advantage retained over 91% of current membership for 2026 through renewals and expects solid growth with new public and private sector clients.

Negatives

• Q3 2025 GAAP EPS of $1.62 was significantly lower than Q3 2024 GAAP EPS of $3.98.
• Full Year 2025 GAAP EPS guidance was revised down to approximately $12.26 from the previous estimate of approximately $13.77.
• Consolidated operating cash flows for YTD 2025 decreased to $2,573 million from $3,494 million in YTD 2024, primarily due to unfavorable working capital items.
• Individual Medicare Advantage membership is still anticipated to decline by approximately 425,000 members for FY 2025, despite an improved outlook.
• Insurance segment income from operations (GAAP) decreased to $251 million in Q3 2025 from $274 million in Q3 2024.
• CenterWell segment income from operations (GAAP) decreased to $305 million in Q3 2025 from $382 million in Q3 2024.
• CenterWell segment operating cost ratio increased to 93.9% in Q3 2025 from 91.3% in Q3 2024.
• The company recognized charges associated with value creation initiatives, primarily related to severance in connection with workforce optimization and external consulting spend.
• The operating leverage impact associated with the loss of individual Medicare Advantage membership negatively affected operating cost ratios.
• CenterWell Primary Care saw a reduction of 2 centers YTD due to ongoing footprint optimization.
• Full Year 2025 net investment income is anticipated to be down approximately $100 million year over year.
• Star Rating declines for Bonus Year 2026 are expected to negatively impact quality bonus payments from CMS.
• Medicaid FY 2025 membership growth guidance was reduced to approximately 160,000 from a previous range of 175,000 to 250,000 members, aligning with national Medicaid enrollment trends.
• CenterWell Home Health Episodic Admissions declined by 1.1% in Q3 2025 and 2.2% YTD year-over-year.
• The company is navigating procurement challenges related to recent awards in Texas and Georgia.

Risks

• Profitability could be materially adversely affected if products are not designed and priced properly, premiums are insufficient, clinical initiatives are not implemented effectively, or estimates of benefits expense are inadequate.
• Estimates of future payments for benefit expenses involve extensive judgment and inherent variability, potentially leading to insufficient reserves.
• Failure to effectively implement operational and strategic initiatives, including Medicare initiatives, state-based contract strategy, CenterWell business growth, and the integrated care delivery model, could materially adversely affect the business.
• The number of Medicare Advantage plans rated 4-star or higher will significantly decline in 2025, and a lawsuit challenging the 2025 Star Ratings was rejected, which will negatively impact 2026 quality bonus payments and may significantly adversely affect revenues, operating results, and cash flows.
• Failure to maintain data integrity, implement new information systems, protect proprietary rights, or defend against cyber-security attacks or data security incidents could materially adversely affect the business.
• Involvement in various legal actions, disputes, governmental and internal investigations, which if resolved unfavorably, could result in substantial monetary damages or changes in business practices and increased costs.
• As a government contractor, the company is exposed to risks such as loss of material government contracts, governmental audits and investigations, potential inadequacy of government determined payment rates, and restrictions on profitability.
• Changes to the risk-adjustment model utilized by CMS or retrospective recovery of previously paid premiums (e.g., Final RADV Rule) could have a material adverse effect on operating results, financial position, and cash flows.
• Substantial government regulation, new laws or regulations, or changes in their application could increase costs and materially adversely affect results of operations, financial position, and cash flows.
• Failure to manage acquisitions, divestitures, and other significant transactions successfully may have a material adverse effect.
• Failure to develop and maintain satisfactory relationships with providers of care to members could adversely affect the business.
• Significant competition in attracting and retaining talented employees, and failure to manage succession for and retention of key executives, could adversely affect the company's success.
• The pharmacy business is highly competitive and subjects the company to regulations and supply chain risks; changes in prescription drug industry pricing benchmarks may adversely affect financial performance.
• Ability to obtain funds from certain licensed subsidiaries is restricted by state insurance regulations.
• Downgrades in debt ratings, should they occur, may adversely affect the business, results of operations, and financial condition.
• Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of the investment portfolio and investment income.

Future Outlook

The company affirmed its Full Year 2025 Adjusted EPS guidance of approximately $17.00 and improved its individual Medicare Advantage membership decline outlook to approximately 425,000 members. Management is committed to achieving an individual MA pretax margin of at least 3% over time and anticipates doubling this margin in 2026 (normalizing for Stars). Improved retention is expected to drive net membership growth in 2026, with most new sales projected to be on contracts with 4+ Stars. Efforts to strengthen the Stars program are progressing, targeting Top Quartile Stars results in Bonus Year 2028. Medicaid margin improvement is anticipated in 2025 as new states mature, and CenterWell Primary Care margins are expected to improve due to J curve maturation and v28 mitigation. The fourth quarter Insurance segment benefit ratio is projected to be approximately 93.5%, with the full year ratio at the top end of the 90.1% to 90.5% range. The Doc Fix for 2026 was included in the One Big Beautiful Bill Act. Detailed 2026 guidance will be provided on the fourth quarter 2025 earnings call in early 2026.

Management Comments

• "Our strategy of putting the consumer at the heart of everything we do is working, with solid year to date performance and strong momentum heading into the Annual Election Period."
• "We feel positive about the direction we're headed and the value we are creating for our members, patients and investors."
• Committed to achieving individual Medicare Advantage pretax margin of at least 3% over time.
• Remains confident in the overall assumptions utilized in 2026 MA pricing and continues to anticipate doubling individual MA pretax margin in 2026 (normalizing for Stars).
• Views membership growth as positive, supported by 2026 MA pricing and the plan and benefit repositioning driven in the prior two years.
• Confident in levers available to moderate new sales volume for 2026 if it impacts operational capacity to deliver an exceptional experience that fuels member retention.

Industry Context

The company's performance and outlook are significantly influenced by the U.S. healthcare regulatory environment, particularly changes related to Medicare Advantage and Medicaid programs. The Inflation Reduction Act (IRA) is noted for its impact on Medicare premiums and Part D seasonality. The ongoing legal dispute and court decision regarding CMS Star Ratings highlight the critical role of regulatory compliance and quality metrics in the Medicare Advantage market. The focus on value-based care models through CenterWell and OneHome reflects a broader industry trend towards integrated care delivery and patient outcome improvement. National Medicaid enrollment trends also impact the company's state-based contract performance.

Comparison to Industry Standards

• NA

Legal Proceedings

• Humana filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of its Medicare Advantage plans.
• On October 14, 2025, the Court issued a decision rejecting Humana's challenge to the 2025 Star Ratings.
• The company is considering its options in this matter, noting that the decline in Star Ratings will negatively impact 2026 quality bonus payments.
• Accrued $15 million in anticipated expenses in connection with a legal matter, recorded as settlement of certain litigation expenses in Q3 2025 and YTD 2025.

Stakeholder Impact

• Shareholders: Mixed financial results with affirmed Adjusted EPS but lowered GAAP EPS guidance and decreased operating cash flow. Potential negative impact on 2026 quality bonus payments due to Star Ratings decline. Strategic growth in CenterWell and Medicaid offers long-term potential.
• Members/Patients: Incremental investments are being made to improve member and patient outcomes. Growth in CenterWell Primary Care and Pharmacy services, along with preparations for new integrated dual eligible programs, aim to enhance healthcare experience and access.
• Employees: Value creation initiatives include severance charges and workforce optimization, indicating potential impacts on employment.
• Providers: Payments to providers are made in accordance with risk-sharing arrangements. The company emphasizes developing and maintaining satisfactory relationships with providers.
• Government/Regulators: Ongoing legal dispute with CMS over Star Ratings and exposure to risks as a government contractor, including potential inadequacy of government payment rates and regulatory changes.

Next Steps

• Actively preparing for the January 1, 2026 launch of the initial phase-in of the Michigan Highly Integrated Dual Eligible Special Needs Plan (HIDE SNP) and the statewide Illinois Fully Integrated Dual Eligible Special Needs Plan (FIDE) programs.
• Preparing for the carve-in of dual eligibles into the South Carolina Medicaid program on January 1, 2026.
• Considering options regarding the lawsuit challenging 2025 Star Ratings after the court rejected the challenge on October 14, 2025.
• Continuing to pursue the sale of additional non-core assets and making progress on capital optimization.
• The acquisition of The Villages Health is expected to close in the fourth quarter.
• Focusing on achieving Top Quartile Stars results in Bonus Year (BY) 2028 through ongoing initiatives.
• Will provide detailed 2026 guidance on the fourth quarter 2025 earnings call in early 2026.

Key Dates

Recommendation

While Humana affirmed its full-year Adjusted EPS guidance and showed improved Medicare Advantage membership retention, the significant reduction in GAAP EPS guidance and a decline in operating cash flows present a mixed financial picture. The confirmed negative impact of the Star Ratings lawsuit for 2026 is a notable headwind. Strategic growth in CenterWell and Medicaid, along with efforts to improve future Star Ratings and MA margins, offer long-term potential. However, the immediate challenges and uncertainties warrant a cautious "hold" stance until there is clearer evidence of sustained GAAP profitability improvement and successful mitigation of Star Ratings impacts.

Keywords

Humana, Medicare Advantage, Healthcare, Insurance, CenterWell, Medicaid, EPS, Financial Results, Q3 2025, Guidance, Star Ratings, Risk Adjustment, Pharmacy, Primary Care, Health Benefits, SEC Filing